Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Launched by JANSSEN-CILAG LTD. · May 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called guselkumab to see how well it can help heal all layers of the digestive tract in patients with Crohn's disease. The goal is to achieve something called "transmural healing," which means healing the entire wall of the intestine. Researchers will measure the effectiveness of the treatment using a special scan after 48 weeks, looking for improvements in the condition of the digestive tract.

To be eligible for this study, participants must have been diagnosed with Crohn's disease for at least three months and show signs of active disease. They should have a specific level of disease activity based on a scoring system, and they need to have not responded well to standard treatments in the past. Patients can expect to receive the medication, have regular check-ups, and undergo scans to monitor their progress. It's important to know that certain complications or recent surgeries may prevent someone from participating in this trial, so discussing individual health situations with a doctor is essential.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Has luminal Crohn's disease (CD) of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy
• • Has clinically active CD, defined as a baseline CD activity index (CDAI) score greater than or equal to (\>=)220 but \<=450 and either: a. Mean daily stool frequency (SF) count \>=4, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score \>=2, based on the unweighted CDAI component of abdominal pain (AP)
• • Active transmural activity in at least one segment (segmental magnetic resonance index of activity \[MaRIA\] \>= 11)
• • a. Has demonstrated inadequate response/intolerance to conventional therapy; b. Has previously demonstrated lack of initial response (that is, primary non-responders), responded initially but then lost response with continued therapy (that is, secondary non-responders), or was intolerant to a maximum of 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (that is, janus kinase \[JAK\] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents)
• Exclusion Criteria:
• • Has complications of Crohn's disease, such as symptomatic strictures or stenoses (unless less than \[\<\]3 centimeter (cm) dilatation and not symptomatic or displaying associated fistula/fistulae and/or or abscess), fibrotic stenosis, internal fistulas, short gut syndrome, or any other manifestation, that might be anticipated to require surgery, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab
• • Currently has or is suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks before baseline, or 8 weeks before baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery. Participants with active perianal fistulas may be included if there are no associated stenoses, no anticipated surgery and no abscesses currently identified
• • Has had any kind of bowel resection within 6 months, or any other intra-abdominal or other major surgery within 12 weeks before baseline
• • Has a draining (that is, functioning) stoma or ostomy
• • Has a stool culture or other examination positive for an enteric pathogen, including Clostridioides difficile (formerly known as Clostridium difficile) toxin, in the previous 4 months, unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen